公司股价与市场表现 - RBC Capital将公司目标价设定为209美元，较当前191.30美元的交易价有约9.26%的潜在上涨空间 [1][6] - 公司当前股价为191.29美元，微涨0.11%，当日交易区间在190.31美元至192.06美元之间 [5] - 公司市值约为4606.9亿美元，过去一年股价最高达192.1美元，最低为140.68美元 [5] 财务业绩与预期 - 公司将于10月14日公布第三季度财报，预计每股收益为2.76美元，高于去年同期的2.42美元 [3] - 预期第三季度营收为237.6亿美元，较去年同期的224.7亿美元有所增长 [3] 产品研发与监管进展 - 美国FDA已批准公司产品Simponi用于中重度活动性溃疡性结肠炎儿童患者 [4] - 该药物获批后，公司股价上涨0.7%，收于191.08美元 [4] 战略发展与投资 - 公司可能收购Protagonist Therapeutics，此举旨在扩大其制药产品组合 [2] - 收购谈判仍在进行中，显示出公司积极寻求增长机会的战略方向 [2]

Johnson & Johnson (NYSE:JNJ) will release earnings results for the third quarter, before the opening bell on Tuesday, Oct. 14.Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.76 per share, up from $2.42 per share in the year-ago period. Johnson & Johnson projects quarterly revenue of $23.76 billion, compared to $22.47 billion a year earlier, according to data from Benzinga Pro.On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's S ...

Johnson & Johnson (NYSE:JNJ) will release earnings results for the third quarter, before the opening bell on Tuesday, Oct. 14.Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.76 per share, up from $2.42 per share in the year-ago period. Johnson & Johnson projects quarterly revenue of $23.76 billion, compared to $22.47 billion a year earlier, according to data from Benzinga Pro.On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's S ...